Bayer shores up contraceptive offering with Conceptus buy
This article was originally published in Clinica
German firm Bayer has expanded its contraceptive offering by agreeing to purchase device developer Conceptus for $1.1 billion, or $31 per share. The move highlights pharma’s continued appetite for traditional medical devices, even though Clinica recently noted that pharmaceutical players are reluctant to buy into the in vitro diagnostics space (www.clinica.co.uk, 4 April 2013). Bayer expects the deal to close by mid-2013.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.